HyperMed detects $4M in new first-round tranche

By Mass High Tech

Nanocomp nabs SBIR funds for bigger sheets [January 9, 2009]

Policy Tracker: Regional SBIR/STTR program in Maine [July 3, 2008]

DRC draws in $268M defense systems deal [May 13, 2008]

Maine's Telford lands $26M Army contract [May 5, 2008]

HyperMed Inc. has closed on $4 million in a new wave of Series A financing to market its hyperspectral medical imaging product, OxyVu, the life sciences company reports.

Mass High Tech reported the Burlington-based company’s plans to close the financing in a March 14 story in which CEO Mark Carbeau describes his commercialization strategy for OxyVu.

GBP Capital, formerly Greenwich Biotech Partners, provided the funds for HyperMed’s latest tranche of Series A financing, and the Connecticut private capital firm also was the sole investor in the company’s $5 million, initial Series A round in 2007.

HyperMed’s lead product, OxyVu, is approved in the United States to assess tissue of patients with diabetic ulcers and peripheral arterial disease, according to the company. The system’s hyperspectral technology includes optics systems and algorithms to detect the amount of oxygen in tissue, and the Department of Defense initially used it for aerial espionage and satellite surveillance.

The medical imaging company was founded in 1999 and employed 24 people as of March 2008.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.